Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a small-molecule inhibitor that targets ROCK1 and ROCK2 with nanomolar potency and remarkable selectivity (>200-fold versus other kinases). It disrupts Rho-mediated stress fiber formation, enhances stem cell viability, and suppresses tumor invasion in vitro and in vivo (Zhu et al., 2023). The compound is highly soluble in DMSO, ethanol, and water, with stock solutions stable at -20°C for several months. Extensive studies validate its use in cytoskeletal, cancer, and regenerative medicine research (ApexBio A3008).

Biological Rationale

ROCK1 and ROCK2 are serine/threonine kinases central to the Rho/ROCK signaling pathway. This pathway regulates actin cytoskeleton dynamics, cell cycle progression, and contractility. Dysregulation is linked to increased tumor invasion, metastasis, and abnormal cell proliferation. In neural tissue, Rho/ROCK modulates neuronal migration and synaptic plasticity (Zhu et al., 2023). Selective inhibition of ROCK isoforms is crucial for mechanistic studies, as off-target kinase inhibition can confound phenotypic outcomes. Y-27632 dihydrochloride offers a tool with validated specificity, enabling controlled modulation of ROCK activity in diverse biological systems.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride inhibits the catalytic domains of ROCK1 (IC₅₀ ≈ 140 nM) and ROCK2 (K_i ≈ 300 nM). It competes with ATP binding, blocking substrate phosphorylation. This inhibition prevents downstream phosphorylation of proteins such as myosin light chain (MLC), LIM kinase, and cofilin. As a result, actin stress fiber assembly and focal adhesion formation are disrupted. The compound does not significantly inhibit other kinases such as PKC, PKA, MLCK, or PAK at relevant concentrations (selectivity >200-fold) (ApexBio A3008). Inhibition of the Rho/ROCK pathway modulates cell morphology, proliferation, and migration. In stem cell cultures, Y-27632 prevents apoptosis and supports single-cell survival, especially during dissociation and expansion.

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC₅₀ of ~140 nM and ROCK2 with a K_i of ~300 nM under in vitro kinase assay conditions (ApexBio A3008).
• It shows >200-fold selectivity against PKC, PKA, MLCK, and PAK in enzymatic assays, minimizing off-target effects (ApexBio A3008).
• In cell-based studies, Y-27632 reduces stress fiber formation and focal adhesions within 30–60 minutes at 10 μM in fibroblasts (Zhu et al., 2023).
• Stem cell viability is enhanced upon addition of 10 μM Y-27632 during cell dissociation, with survival improvements exceeding 2-fold in hPSC cultures (Zhu et al., 2023).
• In vivo, Y-27632-treated mouse models exhibit reduced tumor invasion and metastasis, with histological evidence of diminished pathological structures (Zhu et al., 2023).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is employed in:

• Stem cell biology: Enhancing survival of hPSCs, iPSCs, and neural progenitors, especially during passaging and single-cell dissociation (Precision ROCK Inhibition article). This article expands on practical workflow integration compared to the interlinked piece, focusing on direct experimental considerations.
• Cancer research: Suppressing cellular invasion, modulating cytoskeletal structure, and facilitating tumor microenvironment studies (Advancing Cytoskeletal and Tumor Studies). Here, we provide updated in vivo outcomes and quantitative benchmarks.
• Cell cycle and cytokinesis: Arresting cell cycle progression (G1 to S phase), inhibiting cytokinesis, and controlling proliferation in smooth muscle and tumor cells.
• Neuroscience: Improving survival of transplanted interneurons and promoting integration in epilepsy models (Zhu et al., 2023).

Common Pitfalls or Misconceptions

• Y-27632 is not effective as a universal apoptosis inhibitor; its protective effects are context- and cell-type-specific.
• The compound does not induce differentiation of stem cells; it primarily enhances survival during stressful manipulations.
• Long-term storage of aqueous stock solutions (>1 week) leads to degradation and reduced potency; always store as a dry solid or in DMSO at -20°C.
• Off-target effects may occur at concentrations significantly above 10–50 μM; always titrate to the minimal effective dose.
• Y-27632 does not inhibit all Rho family kinases—its selectivity is specific for ROCK1/2.

Workflow Integration & Parameters

Solubility: Y-27632 dihydrochloride is soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water. Warm to 37°C or use an ultrasonic bath to enhance dissolution.

Storage: Store solid at 4°C or below, desiccated. Stock solutions in DMSO remain stable at -20°C for several months (ApexBio A3008).

Experimental Use: Typical working concentrations range from 1–20 μM. For stem cell protection during dissociation, 10 μM is standard. For cytoskeletal studies, preincubate cells for 30–60 min prior to downstream assays. For in vivo studies, dosing regimens vary by model; consult primary literature for guidance (Zhu et al., 2023).

For further details and validated protocols, refer to the Y-27632 dihydrochloride product page and relevant application notes.

Conclusion & Outlook

Y-27632 dihydrochloride is a foundational compound for dissecting Rho/ROCK pathway function and modulating cytoskeletal dynamics. Its robust selectivity and well-established benchmarks make it suitable for a broad range of cell biology, neuroscience, and oncology applications. As new evidence emerges, such as the use of chemically matured interneurons in epilepsy therapy (Zhu et al., 2023), Y-27632 is poised to remain central in translational research workflows. For more advanced applications and strategic perspectives, see the companion deep dives on Strategic ROCK Inhibition, which this article updates with quantitative experimental guidance.